CLPTM1L and lung carcinoma: Given reports of copy number gain in lung cancer, GWAS evidence, and increased expression of CLPTM1L in cisplatin resistant ovarian tumor cells, we sought to determine if CLPTM1L was overexpressed in lung tumors.